Patrick Lin Acquires Shares in Processa Pharmaceuticals

Patrick Lin, a top executive, purchased 1,831 shares of Processa Pharmaceuticals.

Written by EarningsIQ · Published Jun 17, 2026, 2:01 AM EDT · Updated Jun 17, 2026, 6:00 AM EDT

Key Points

Patrick Lin purchased 1,831 shares of Processa Pharmaceuticals at $2.22 per share, totaling $4,064.82.
Processa Pharmaceuticals trades on NasdaqCM with a market cap of about $5.75 million and a 52-week high of $14.25.
Analysts like HC Wainwright & Co. maintain a 'buy' rating on PCSA, with targets as high as $8.00.

On June 15, 2026, Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc., bought 1,831 shares of the company. The transaction was made at an average price of $2.22 per share, totaling approximately $4,064.82. This purchase was not part of a pre-planned trading program.

Insider Buying and Selling at Processa Pharmaceuticals, Inc.

Several insiders at Processa Pharmaceuticals were active on June 15, 2026. Alongside Patrick Lin, Chief Executive Officer George Ng acquired 2,465 shares, while David Young, President of Research & Development, purchased 2,067 shares. Chief Financial Officer Russell Skibsted bought 2,654 shares, and Chief Administrative Officer Wendy Guy acquired 2,118 shares, all at $2.22 per share. These transactions were not pre-planned.

Other Institutional Activity in Processa Pharmaceuticals

Among institutional investors, Stonepine Capital Management, LLC significantly increased its stake in Processa Pharmaceuticals by adding 42,677 shares, ending with 55,000 shares valued at approximately $138,875. Geode Capital Management, LLC also boosted its holdings by 9,585 shares, reaching a total of 24,908 shares worth about $62,768. Conversely, UBS Group AG reduced its position by 10,109 shares, leaving it with 2,531 shares valued at $6,391.

Processa Pharmaceuticals Stock Snapshot

Shares of Processa Pharmaceuticals, Inc. (NasdaqCM: PCSA) recently traded around $2.09. The company has a market capitalization of approximately $5.75 million. Processa's stock has seen a 52-week low of $1.76 and a high of $14.25. The stock's 50-day moving average is $2.69, and its 200-day moving average stands at $4.32. Despite a negative EPS of -4.07, the company does not have a meaningful P/E ratio as it is not currently profitable.

Analysts Set New Price Targets

Analysts at HC Wainwright & Co. have maintained a 'buy' rating on Processa Pharmaceuticals. On September 2, 2025, they set a price target of $1.00. Previously, on June 30, 2025, they reiterated a target of $2.00. Earlier, on December 8, 2024, they had a target of $6.00. The consensus among analysts suggests a positive outlook with a mean target price of $2.00 based on recent evaluations.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Vero Beach, Florida. It focuses on developing cancer therapy drugs to enhance the safety and efficacy of cancer treatments. The company modifies existing FDA-approved oncology drugs to alter their metabolism and distribution while preserving their cancer-killing mechanisms. Its pipeline includes PCS6422 for solid tumors and PCS11T for various cancers, along with non-oncology drugs like PCS499 and PCS12852 for other medical conditions. Founded in 2015, the company operates with a small team of 12 employees.

Bottom Line

Patrick Lin's recent purchase of Processa Pharmaceuticals shares highlights insider confidence in the company. While the stock is currently trading significantly below its 52-week high, institutional investors have shown mixed activity, with some increasing their stakes. Analysts remain optimistic, maintaining 'buy' ratings with varying price targets. As always, it's important to remember that 13F filings and insider transactions reflect past actions and may not indicate current or future positions.